Chen Z, et al. - Researchers investigated whether matrix metalloproteinase 19 (MMP19; a member of zinc-dependent endopeptidases) can serve as a valuable prognostic predictor in colorectal cancer (CRC) patients. They used The Cancer Genome Atlas (TCGA) cohort to first explore the MMP19 expression, which was then validated in the GSE39582 cohort and their own database. Both univariate and multivariate survival analyses in the TCGA database revealed the predictive ability of MMP19 for overall survival. Univariate analysis and multivariate analysis of GSE39582 database further validated MMP19 as an independent factor for recurrence free survival. In CRC, an upregulated MMP19 expression was found and high expression of MMP19 was found to be an independent and poor prognostic factor. Overall, MMP19 could be a good biomarker for CRC.